Clinical trial
Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
NCT00491816 · University of Kansas Medical Center, Other · Unknown status
Key facts
| NCT number | NCT00491816 |
|---|---|
| Title | Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer |
| Official title | Phase II Trial of Neoadjuvant Erlotinib Plus Chemotherapy for Treatment of ER Negative, PgR Negative and HER-2 Negative Primary Breast Cancer |
| Lead sponsor | University of Kansas Medical Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Erlotinib with neoadjuvant chemotherapy |
| Enrollment | 32 |
| Start date | Jul 1, 2007 |
| Primary completion | Dec 1, 2014 |
| Completion | Dec 1, 2017 |
| First posted | Jun 26, 2007 |
| Last update posted | Jan 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: